行情

XENT

XENT

Intersect ENT
NASDAQ

实时行情|Nasdaq Last Sale

11.73
+0.75
+6.83%
盘后 16:00 04/09 EDT
开盘
11.31
昨收
10.98
最高
11.81
最低
10.75
成交量
59.85万
成交额
--
52周最高
34.28
52周最低
5.97
市值
3.79亿
市盈率(TTM)
-8.5564
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测XENT价格均价为25.00,最高价位30.00,最低价为13.00。

EPS

XENT 新闻

更多
  • Intersect ENT (XENT) Down 49.5% Since Last Earnings Report: Can It Rebound?
  • Zacks · 03/25 16:30
  • XENT Long Term Shareholder Alert: Johnson Fistel Investigates Intersect ENT, Inc.; Should Management be Held Accountable for Investors Losses?
  • GlobeNewswire · 03/18 22:28
  • Insider Buying: The Intersect ENT, Inc. (NASDAQ:XENT) Executive VP & CFO Just Bought US$125k Worth Of Shares
  • Simply Wall St. · 03/18 12:57
  • New Strong Sell Stocks for March 16th
  • Zacks · 03/16 14:38

所属板块

医疗设备、用品及经销
+1.71%
医疗设备和用品
+1.91%

热门股票

代码
价格
涨跌幅

XENT 简况

Intersect ENT, Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care. The Company's commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. The Company markets PROPEL, which is indicated for use following ethmoid sinus surgery, and PROPEL Mini, which is indicated for use following ethmoid and/or frontal sinus surgery.
展开

微牛提供Intersect ENT Inc(NASDAQ-XENT)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的XENT股票新闻,以帮助您做出投资决策。